Screener / SEC EDGAR /CIK 0001377121 /10-K filed Feb 25, 2026, compared with Feb 21, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Protagonist Therapeutics, Inc PTGX

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of PTGX's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Sep 21, 2017
Questions asked 27 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 27 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 0 of 2 closing letter

Filing review

2017-09-21 to 2017-10-03 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
Prospectus Cover Page
SEC asked
It appears that the aggregate market value of your voting and non-voting common equity held by non-affiliates during the 60 days prior to the date of filing of the registration statement may not have exceeded $75 million, as required by General Instruction I.B.1 of Form S-3. Please provide us your analysis demonstrating your ability to use Form S-3.
Rest of the question

Alternatively, please revise your prospectus cover page to disclose the calculation of the aggregate market value of your outstanding voting and non-voting common equity and the amount of all securities offered pursuant to General Instruction I.B.6 during the prior 12 calendar month period that ends on, and includes, the date of the prospectus. Refer to Instruction 7 to General Instruction I.B.6.

PTGX answered
The Company advises the Staff that it meets the public float requirements set forth in General Instruction I.B.1 of Form S-3. General Instruction I.B.1 requires the aggregate market value of the voting and non-voting common equity held by non-affiliates of a company to be at least $75 million.

The instruction to General Instruction I.B.1 states that the computation of the aggregate market value of the voting and non-voting common equity held by non-affiliates of a company shall be computed using the price at which the common equity was last sold, or the average of the bid and asked prices of
Rest of the answer

such common equity, in the principal market for such common equity as of a date within 60 days prior to the date of filing.

Cooley LLP 3175 Hanover Street Palo Alto, CA 94304-1130 t: (650) 843-5000 f: (650) 849-7400 cooley.com

Page Two

The Company filed the Registration Statement on September 1, 2017. As of August 31, 2017, there were 16,909,609 shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), outstanding, which is the only class of voting and non-voting common equity of the Company currently outstanding. As of such date, the closing per share sales price of the Common Stock on the NASDAQ Global Market (the principal market for the Common Stock) was $16.33, as reported by The Wall Street Journal. Accordingly, the aggregate market value of the Company’s outstanding voting and non-voting common equity as of August 31, 2017 was approximately $276,133,914.

As of August 31, 2017, (i) 9,699,872 shares of the Company’s Common Stock were held by non-affiliates of the Company and (ii) 7,209,737 shares of the Company’s Common Stock were held by affiliates of the Company, consisting of the Company’s directors, executive officers and the following stockholders: Canaan X L.P. (“Canaan”), Johnson & Johnson Development Corporation (“JJDC”) and Lilly Ventures Fund I, LLC (“Lilly Ventures”). As such, the aggregate market value of the Company’s voting and non-voting common equity held by non-affiliates was $158,398,909 on August 31, 2017.

The Company has determined that its directors, executive officers, Canaan, JJDC and Lilly Ventures are the only “affiliates” of the Company, as that term is defined in Rule 405 of the Securities Act of 1933, as amended. Canaan, JJDC and Lilly Ventures are large stockholders of the Company, holding approximately 14.5%, 14.5% and 12.4%, respectively. Each of these stockholders owned stock in the Company prior to the Company’s initial public offering (the “IPO”), had representatives on the Company’s board of directors prior to the IPO and, in the case of Canaan and Lilly Ventures, continue to have a representative on the Company’s board of directors.

To the Company’s knowledge, the only other stockholders owning 5% or more of the Company’s Common Stock are Adage Capital Partners, LP, FMR LLC and Pharmstandard International, S.A. (each, an “Other 5% Holder” and collectively, the “Other 5% Holders”). However, the Company does not consider any of the Other 5% Holders to be an affiliate of the Company because of the passive nature of their investments, their lack of representation on the Company’s board of directors and inability, by contract or otherwise, to affect the management or policies of the Company.

Given the lack of any control relationship between any of the Other 5% Holders and the Company, the Company has concluded that none of the Other 5% Holders is an affiliate of the Company. If FMR LLC, the largest non-affiliate stockholder of the Company, were characterized as an affiliate, the aggregate market value of the Company’s outstanding voting and non-voting common equity held by non-affiliates would still be greater than $75 million as of August 31, 2017.

Based on the foregoing, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the Company as of August 31, 2017 (a date within 60 days prior to the filing of the Registration Statement) is at least as follows:

Aggregate Market Value of Outstanding Common Equity (16,909,609 * $16.33)

$

276,133,914

Minus Aggregate Market Value of Common Equity Held by Affiliates (7,209,737 * $16.33)

117,735,005

Aggregate Market Value of Common Equity Held by Non-Affiliates

158,398,909

Page Three

Based on the foregoing calculations and other information, the aggregate market value of the Company’s outstanding voting and non-voting common equity held by non-affiliates was greater than $75 million as of August 31, 2017. The Company is therefore not relying on General Instruction I.B.6 of Form S-3 and is eligible to use Form S-3 in accordance with General Instruction I.B.1.

**********

Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding the Form S-3 or this response letter to me at (650) 843-5636.

Read in the reply

Also in this review: company letter, Oct 3, 2017

Form S-1

2016-05-27 to 2016-07-11 · 26 questions · 2 letters from the SEC, 1 from the company
No closing letter
Risk factorsResults discussion (MD&A)Critical estimates
Prospectus Summary, page 1 · Overview, page 1
SEC asked (1)
We note your statement that your primary focus is on developing drugs that “specifically target biological pathways that have been clinically validated through U.S. Food and Drug Administration (FDA) approved injectable antibody drugs.” As currently drafted, this statement could imply that the FDA has approved, or will more easily approve, your products.
Rest of the question

Although your drugs may target certain pathways that have been used by other drugs, we note that your drug is still distinct from prior drugs that have been approved by the FDA. While it is appropriate to say that you are using a similar pathway to help guide your development program, please revise your disclosure to remove any implication that your product candidates are more likely to receive FDA approval than others. Please also remove the statement that you have a “de-risked and differentiated competitive advantage.” Please make similar revisions throughout your prospectus, including in your Business section, as necessary.

PTGX answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1 · Overview, page 1
SEC asked (2)
At first use, please define any significant scientific or technical terms in order for a lay investor to understand. As examples, please define the terms “integrin specific antagonist peptid,” “hepcidin mimetic,” and “cytokine.”
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1 · Overview, page 1
SEC asked (3)
Please tell us why you believe that your product candidates are “best-in-class” and “first-inclass.”
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1 · Overview, page 1
SEC asked (4)
The table of your pipeline product candidates on pages 2 and 82 should reflect the actual, and not the anticipated, status of your pipeline candidates as of the latest practicable date. The table currently suggests that PTG-100 has completed Phase 1 testing but your disclosure says that the Phase 1 testing is still ongoing.
Rest of the question

Similarly, the table suggests that both PTG-200 and PTG-300 have completed preclinical studies, when your disclosure states that both candidates are still in preclinical. Please also revise the table to reflect the difference in stages of PTG-200 and PTG-300, as the table currently indicates that they are equal. Finally, please remove the “undisclosed agonist” from the table. The table is intended to provide information about actual products. Unless an indication and a compound have been identified, the product is too preliminary for inclusion in the table.

PTGX answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1 · Overview, page 1
SEC asked (5)
We note your reference to Entyvio both here and in your business section. Please tell us whether you are using data from Entyvio as part of your IND submission and whether you have any agreements with the company to use this data. If you are not using this data, please clearly state what specifically you are using from Entyvio and how it impacts your development of PTG-100.
Rest of the question

In addition, please remove your statement that you can “de-risk” the development of PTG-100 by leveraging the regulatory path of Entyvio, and your statement on page 90 that your targeted approval for IBD has been “validated” by the 2014 FDA approval of Entyvio. Please also revise your disclosure throughout to remove any implication that the safety and efficacy results for Entyvio mean that you will have similar safety and efficacy results for PTG-100.

PTGX answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1 · Overview, page 1
SEC asked (6)
On page 94 your state that you utilized a liquid formulation in your Phase 1 clinical trial but will introduce a capsule formulation in your Phase 2b clinical trial. We note that you plan to conduct a bridging study to evaluate the bioavailability of the capsule formulation versus the liquid formulation.
Rest of the question

Your current disclosure states that you plan to file an IND by the end of the third quarter of 2016 for Phase 2b trials and that you plan to utilize a capsule formulation. Please tell us whether you will be able to rely on your Phase 1 results given that they were conducted using a liquid formulation and whether you are still on track to file an IND by the end of the third quarter.

PTGX answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1 · Overview, page 1
SEC asked (7)
In the first bullet point under “Risks Related to Our Business” please quantify your operating losses for the most recent fiscal year and your total accumulated deficit.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Risk Factors, page 12
SEC asked (8)
We note that your restated certificate of incorporation includes an exclusive forum provision. Please add a risk factor to disclose that such a provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes, and may discourage lawsuits with respect to such claims against the company and its officers, directors or other employees.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Risks Related to Our Intellectual Property, page 37
SEC asked (9)
The risk factors throughout this section suggest that you have multiple issued patents. However, we note that the disclosure on page 104 indicates that you only have one issued patent. Please revise your disclosure throughout this section to reflect this fact.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Critical Accounting Policies and Estimates · Stock-Based Compensation, page 73
SEC asked (10)
We may have additional comments on your accounting for equity issuances including stock compensation and beneficial conversion features. Once you have an estimated offering price, please provide us an analysis explaining the reasons for the differences between recent valuations of your common stock leading up to the IPO and the estimated offering price.
PTGX answered
The

Company has advised us that it has granted stock options during the period from January 1, 2015 through the date of this letter as follows:

[*] Certain confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant to 17

C.F.R.
Rest of the answer

§200.83.

COOLEY LLP 3175 HANOVER STREET PALO ALTO, CA 94304-1130

Page Three

Grant date

Number of shares underlying stock options granted

Exercise price per share of common stock

Estimated fair value

March 26, 2015

637,893

$

0.13

October 28, 2015

5,287,261

0.08

February 8, 2016

894,163

April 29, 2016

7,634,466

0.29

July 16, 2016

813,318

0.42

As stated in the Registration Statement, stock-based compensation expense related to stock options granted to employees is measured at the date of grant based on the estimated fair value of the award, net of estimated forfeitures. The Registration Statement describes the Company’s use of the Black-Scholes option-pricing model for these purposes and describes the significant assumptions used during the years ended December 31, 2014 and 2015 and the three months ended March 31, 2016. The Company will reevaluate each of these assumptions, and update them as appropriate, when granting new equity awards and in preparing its financial statements for the remainder of 2016.

Historical Stock-Based Compensation Expense

The Company’s stock-based compensation expense for the years ended December 31, 2014 and 2015 and the three months ended

March 31, 2016 were approximately $42,000 (0.5% of total operating expenses), $99,000 (0.7% of total operating expenses) and $56,000 (0.8% of total operating expenses), respectively.

Stock Option Grants and Common Stock Valuations

The estimated fair value of the common stock underlying stock options was determined at each grant date by the Company’s board of directors and was supported by periodic independent third-party valuations. The Company’s board of directors intended all options granted to be exercisable at a price per share not less than the per-share fair value of the common stock underlying those options on the date of grant. The valuations of common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company

Equity Securities Issued as Compensation (the “Practice Aid”). The methodology used by the third-party valuation specialists to determine the fair value of the Company’s common stock included estimating the fair value of the enterprise, subtracting the fair value of debt from this enterprise value, and then allocating this value to all of the equity interests using the option pricing method or the probability weighted expected return method. The assumptions used in the valuation model to determine the estimated fair value of the Company’s common stock as of the grant date of each

[*] Certain confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant to 17

Page Four option are based on numerous objective and subjective factors, combined with management judgment, including the following:

• the Company’s stage of development progress of the Company’s research and development efforts;

the impact of significant corporate events or milestones;

material risks related to the business;

the Company’s actual operating results and financial condition, including the Company’s level of available capital resources;

rights, preferences and privileges of the preferred stock relative to those of the common stock;

equity market conditions affecting comparable public companies;

the likelihood and potential timing of achieving a liquidity event for the shares of common stock, such as an initial public offering given prevailing market and biotechnology sector conditions; and that the grants involved illiquid securities in a private company.

Common stock valuation methodologies

The valuations discussed below were performed in accordance with applicable elements of the Practice Aid. The Practice

Aid prescribes several valuation approaches for estimating the value of an enterprise, such as the cost, market and income approaches, and various methodologies for allocating the value of an enterprise to its common stock.

The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, the Company considered the following methods:

Option Pricing Method. Under the option pricing method (“OPM”) shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options.

Probability-Weighted Expected Return Method. The probability-weighted expected return method (“PWERM”) is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment

[*] Certain confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant to 17

Page Five returns, considering each of the possible outcomes available to the Company, as well as the economic and control rights of each share class.

Based on the Company’s early stage of development and other relevant factors, the Company determined that OPM was the most appropriate method for allocating the Company’s enterprise value to determine the estimated fair value of common stock for valuations performed during July 2014 and July 2015. Beginning in December 2015, the Company has used PWERM in combination with OPM

(the “Hybrid Approach”) to determine the estimated fair value of the Company’s common stock.

Common stock valuations

In determining the estimated fair value of the common stock underlying the stock options granted, the Company’s board of directors considers the most recent contemporaneous independent third-party valuation of the Company’s common stock and an assessment of additional objective and subjective factors it believes to be relevant as of the grant date. The additional factors considered when determining any changes in estimated fair value between the most recent contemporaneous valuation and the grant date include, when applicable, the prices paid in the Company’s recent financing transactions, the Company’s stage of development, the Company’s clinical, operating and financial performance and business and financial market conditions generally and in the biotechnology sector. Each of the stock option grant dates since

January 1, 2015 is discussed below.

March 26, 2015. The Company received an independent third-party valuation of its common stock as of July 31, 2014 that indicated that the fair value of the common stock on that date was $0.13 per share. This valuation utilized the OPM “backsolve” method to estimate the Company’s equity value based on the

Company’s Series B convertible preferred stock financing. This equity value was then allocated using OPM to the securities outstanding based on their liquidation preferences and other rights. The independent valuation specialist used an estimated volatility of 41% and an expected time to liquidity event of 2.0 years and applied a 35% discount for lack of marketability due to the Company being privately held. Between July 31, 2014 and March 26, 2015, there were no substantive changes in the Company’s financial position or commercial prospects that might have caused a change in fair value or warranted an updated independent third-party valuation. The Company’s board of directors determined the estimated fair value of the Company’s common stock to be $0.13 per share as of March 26, 2015.

October 28, 2015.

The Company received an independent third-party valuation of its common stock as of July 31, 2015 that indicated that the fair value of the common stock on that date was $0.08 per share. This valuation utilized the OPM “backsolve” method to estimate the Company’s equity value based on the July 2015 Series C convertible preferred stock financing.

[*] Certain confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant to 17

Page Six

This equity value was then allocated using OPM to the securities outstanding based on their liquidation preferences and other rights. The independent valuation specialist used an estimated volatility of 59% and an expected time to liquidity event of 2.5 years and applied a 35% discount for lack of marketability due to the Company being privately held. Between July 31, 2015 and October 28, 2015, there were no substantive changes in the Company’s financial position or commercial prospects that might have caused a change in fair value or warranted an updated independent third-party valuation. The Company’s board of directors determined the estimated fair value of the Company’s common stock to be $0.08 per share as of October 28, 2015.

February 8, 2016. The Company received an independent third-party valuation of its common stock as of December 31, 2015 that indicated that the fair value of the common stock on that date was $0.06 per share. This valuation utilized the Hybrid Method to estimate the

Company’s equity value. Using the Hybrid Method, two scenarios were assumed, a dissolution scenario using the PWERM and the closing of an additional tranche of the Series C convertible preferred stock financing scenario in six months using the

OPM. In the additional tranche preferred stock financing scenario, the independent valuation specialist used an estimated volatility of 57% and an expected time to liquidity event of 1.6 years and applied a 35% discount for lack of marketability due to the Company being privately held. The Hybrid Method weighted the additional tranche preferred stock financing scenario at 69% and the dissolution scenario at 31%. Between December 31, 2015 and February 8, 2016, there were no substantive changes in the Company’s financial position or commercial prospects that might have caused a change in fair value or warranted an updated independent third-party valuation. However, the independent third-party valuation of the Company’s common stock decreased from $0.08 per share as of July 31, 2015 to $0.06 per share as of December 31, 2015 primarily due to fluctuations in U.S. economic conditions and challenges related to raising additional financing for biotechnology companies resulting from the weakening U.S. economy in the fourth quarter of 2015. Because the independent third-party valuation of the Company’s common stock decreased as a result of macroeconomic factors, the Company’s board of directors did not decrease the estimated fair value of the Company’s common stock, and determined it to be $0.08 per share as of February 8, 2016.

April 29, 2016. The Company received an independent third-party valuation of its common stock as of March 31, 2016 that indicated that the fair value of the common stock on that date was $0.29 per share. This valuation utilized the Hybrid Approach to estimate the Company’s equity value. Using the Hybrid Method, two scenarios were assumed, an IPO scenario using the PWERM and an exit/liquidity event scenario using the OPM. Using the PWERM approach, the independent valuation specialist considered three different IPO scenarios. The time to liquidity was estimated to occur between four months and six months of

March 31, 2016 and a 10% discount was applied for lack of marketability due to the Company being privately held. The estimated valuation of the Company in the three different IPO scenarios was estimated to be between $95 million and $157 million. In the exit/liquidity event

[*] Certain confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant to 17 C.F.R. §200.83.

Page Seven scenario, the independent valuation specialist used an estimated volatility of 52% and an expected time to liquidity event of 2.0 years and applied a 35% discount for lack of marketability due to the Company being privately held. The Hybrid Method weighted the IPO scenario at 33% and the exit/liquidity event scenario at 67%. The resulting fair value of the Company’s common stock was $0.29 per share. Between March 31, 2016 and

April 29, 2016, there were no substantive changes in the Company’s financial position or commercial prospects that might have caused a change in fair value or warranted an updated independent third-party valuation. The Company’s board of directors determined the estimated fair value of the Company’s common stock to be $0.29 per share as of April 29, 2016.

July 16, 2016. The Company received an independent third-party valuation of its common stock as of June 30, 2016 that indicated that the fair value of the common stock on that date was $0.42 per share. This valuation utilized the Hybrid Approach to estimate the Company’s equity value. Using the Hybrid Method, two scenarios were assumed, an IPO scenario using the PWERM and an exit/liquidity event scenario using the OPM. Using the PWERM approach, the independent valuation specialist considered three different IPO scenarios. The time to liquidity was estimated to occur between six weeks and eight months of

June 30, 2016 and a 7.5% discount was applied for lack of marketability due to the Company being privately held. The estimated valuation of the Company in the three different IPO scenarios was estimated to be between $100 million and $150 million. In the exit/liquidity event scenario, the independent valuation specialist used an estimated volatility of 53% and an expected time to liquidity event of 2.0 years and applied a 35% discount for lack of marketability due to the Company being privately held. The Hybrid Method weighted the IPO scenario at 50% and the exit/liquidity event scenario at 50%. The resulting fair value of the Company’s common stock was $0.42 per share. Between June 30, 2016 and July 16,

2016, there were no substantive changes in the Company’s financial position or commercial prospects that might have caused a change in fair value or warranted an updated independent third-party valuation. The Company’s board of directors determined the estimated fair value of the Company’s common stock to be $0.42 per share as of July 16, 2016.

Factors contributing to differences between grant date estimated fair values and the estimated IPO price

In recognition of the Staff’s interest in understanding the factors affecting the difference between the anticipated offering price and the estimated fair value of common stock in connection with prior stock option grants, the Company is providing the information set forth below.

2015-2016 Stock Option Grants. The Company believes the following factors, along with those set forth above with respect to each of the options granted by the Company since

[*] Certain confidential information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant to 17 C.F.R. §200.83.

Page Eight

January 1, 2015, explain the difference between the estimated fair values of the Company’s common stock on those grant dates and the estimated IPO price.

The estimated IPO price range represents a future price for shares of common stock that, if issued in the IPO, will be immediately freely tradable in a public market, whereas the estimated fair value of the common stock as of all of the option grant dates described above represents a contemporaneous estimate of the fair value of shares that were then illiquid, might never become liquid and, even if an IPO were successfully completed, would remain illiquid for the

180-day lockup period following the IPO. This illiquidity accounts for a substantial difference between the estimated fair values of the common stock through July 2016 and the estimated IPO price range.

The holders of the Company’s preferred stock currently enjoy substantial economic rights and preferences that are senior to the rights of the holders of its common stock. The price range described assumes the conversion of all of the preferred stock into common stock upon completion of the IPO. The corresponding elimination of these economic rights and preferences results in a higher valuation of the common stock after the IPO than before it.

The successful completion of an IPO would strengthen the Company’s balance sheet, provide access to public equity, provide enhanced operational flexibility and strengthen the Company’s brand recognition.

The Company added highly qualified employees, including a Chief Financial Officer in February 2016.

The Company’s consideration of various objective and subjective factors in the previous fair value determinations, as described above, that are not applicable to the determination of the IPO price range.

Recent improvements in the capital markets provide increased optimism for a successful IPO. For example, the Dow Jones Industrial Average (“DJIA”) closed at an all-time high on July 12, 2016, following a strong June 2016 jobs report by the United States Department of Labor, recovering from dramatic drops in the DJIA in reaction to the June 23, 2016 United Kingdom referendum vote in favor of leaving the European Union.

The IPO price range reflects the fact that investors may be willing to purchase shares in the IPO at a per share price that takes into account other factors that were not expressly considered in the Company’s prior valuations as a private company, and information contained in this letter, marked by brackets, has been omitted and filed separately with the Commission pursuant to 17 C.F.R. §200.83.

Page Nine are not objectively determinable and that valuation models are not able to quantify with any level of certainty.

Based on the foregoing, the Company respectfully seeks confirmation that the Staff has no further comments with respect to the matters discussed in this letter.

Understandings:

The Company has authorized us to advise the Staff that it hereby acknowledges that:

the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
Contractual Obligations and Other Commitments, page 78
SEC asked (11)
Please include in the table the milestone amounts due by type of event (i.e. development, regulatory, sales) under the Research Collaboration and License Agreement with Zealand Pharma A/S discussed under Material Agreements on page 102.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-100: An Oral α4β7 Integrin Antagonist, page 89 · PTG-100’s Pre-Clinical Proof-of-Concept Studies, page 91
SEC asked (12)
Please expand your narrative discussion of Tables 1 and 2 to explain the meaning of all undefined scientific terms and measurements. Please also explain what the numeric results in the table indicate.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-100: An Oral α4β7 Integrin Antagonist, page 89 · PTG-100’s Pre-Clinical Proof-of-Concept Studies, page 91
SEC asked (13)
At first use, please provide a brief explanation of the abbreviation “nd” for a lay investor to understand.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-100: An Oral α4β7 Integrin Antagonist, page 89 · PTG-100’s Pre-Clinical Proof-of-Concept Studies, page 91
SEC asked (14)
At first use, please provide a brief explanation of the term “p-value” and how it is used to measure statistical significance. Please also explain the relevance of statistical significance to the FDA’s evidentiary standards for drug approval.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-100’s Non-GLP and GLP Safety Pharmacology and Toxicology Studies, page 93
SEC asked (15)
Please provide a brief explanation of the term “GLP” at first use.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-100’s Phase 1 Clinical Trial Overview, page 93
SEC asked (16)
We note that you have initiated a Phase 1 clinical trial of PTG-100 in Australia following the submission and approval of a CTN. We also note your statements throughout the prospectus indicating that you intend to initially obtain marketing approval for PTG-100 in the United States. Please explain your reason for commencing clinical trials in Australia, rather than in the United States.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-100’s Phase 1 Clinical Trial Overview, page 93
SEC asked (17)
Please provide a brief explanation of what the results under the column labeled “AUC” in Table 5 indicate.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-200’s Pre-Clinical Proof-of-Concept Studies, page 96
SEC asked (18)
Please expand your narrative discussion of Table 6 to explain the meaning of all undefined scientific terms and measurements. Please also explain what the numeric results in the table indicate.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

PTG-200’s Pre-Clinical Proof-of-Concept Studies, page 96
SEC asked (19)
Please expand your narrative discussion of Figure 8 to explain the results displayed in each graphic in more detail. For example, please provide a brief explanation of “macroscopic score,” what it measures and what your results demonstrate.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Our Peptide Technology Platform, page 99
SEC asked (20)
We note your statement that your “proprietary technology platform has been successfully applied to a diverse set of biological targets that has led to several pre-clinical and clinicalstage peptide-based NCEs…” Please revise this language to clearly indicate that you have only one clinical-stage product candidate at this point.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Material Agreements · Research Collaboration and License Agreement with Zealand Pharma A/S, page 102
SEC asked (21)
We note that “the agreement continues in effect until [you] are no longer entitled to any financial benefit under the agreement.” Please disclose the financial benefits that you are entitled to under this agreement.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Material Agreements · Research Collaboration and License Agreement with Zealand Pharma A/S, page 102
SEC asked (22)
Please disclose the royalty term under this agreement.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

Competition, page 102
SEC asked (23)
To the extent known, please disclose the stage of development of competing product candidates.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

General
SEC asked (24)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
PTGX answered

No numbered answer found in the reply. Read the reply ↗

SEC letter of Jul 5, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
General
SEC asked (1)
We note your response to our prior comment 5. However, the registration statement still contains statements throughout that PTG-100’s and PTG-200’s target and biological pathways have been “clinically validated.” This language implies that your products do not face the same risks as other clinical-phase product candidates. Please delete this language from your disclosure.
PTGX answered

No reply letter found.

General
SEC asked (2)
Please clearly explain whether you are using the data from the clinical trials of the approved products that you reference as part of your IND submission to the FDA. Please also disclose whether you have any agreements or understandings with Takeda Pharmaceutical Company with respect to Entyvio, including your use of the PD biomarker data from Entyvio.
Rest of the question

In the alternative, please disclose that you do not have any relationship with Takeda or any other maker of these approved products.

PTGX answered

No reply letter found.

Letters without questions

Other letters

UPLOAD and CORRESP
8 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 14 letters filed since 2016-05-27. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PTGX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.